Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Multiple fresh catalysts: Q2 2026 revenue of $796M and adjusted EBITDA of $206M beat estimates, full-year 2026 guidance was raised again, July debt repricing lowers interest costs, and recent FDA approvals add product momentum. Stock is up about 10.5% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Improvement ⢠Cash Flow Weakness ⢠Excessive Leverage AMRX's improving margins and liquidity are outweighed by negative quarterly cash flow, rising debt, thin equity, and demanding valuation, warranting caution.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support test ⢠Reclaim trigger Support Level: $16.87â$17.00 Resistance Level: $17.40â$17.55, then $17.90â$18.10 AMRX is mildly bearish over the last month, with price below its 21-day average; hold $16.87â$17.00 support or reclaim $17.55 to stabilize, while a break lower risks further downside.
Sentiment & News
Key News Insights: ⢠Shareholder investigation ⢠Defensive stock mentions ⢠Mixed investor signals Amneal faces legal scrutiny despite being highlighted as a defensive healthcare stock amid market volatility.
AI Summary
AMRX's shift toward specialty drugs and Kashiv biosimilars creates meaningful upside, but the investment case now hinges on converting margin gains into sustained free cash flow and deleveragingâinvestors should wait for clear cash-conversion and integration milestones before assigning full value to the growth pipeline.
Description
Amneal Pharmaceuticals is a manufacturer and distributor of generic and specialty medicines, operating three reporting segments: Generics, Specialty and AvKARE. Its Generics business produces a broad range of dosage forms while the Specialty unit markets branded therapies across several therapeutic areas; AvKARE supplies pharmaceuticals, medical and surgical products, and packaging services primarily to government and institutional customers. The company sells through wholesalers, hospitals and pharmacies, and maintains operations in the United States, India, Ireland and other international markets; it is headquartered in Bridgewater, New Jersey and was founded in 2002.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 3 | Aug 10 | AMRX | Amneal Pharmaceuticals, Inc. | Multiple fresh catalysts: Q2 2026 revenue of $796M and adjusted EBITDA of $206M beat estimates, full-year 2026 guidance was raised again, July debt repricing lowers interest costs, and recent FDA approvals add product momentum. Stock is up about 10.5% over 21 trading days. | Closed | -5.1% |
| Jun 9 | Jun 16 | AMRX | Amneal Pharmaceuticals, Inc. | Positive catalyst stack with FDA approval of romidepsin injection solution including 180 days of exclusivity, solid Q1 2026 revenue/adjusted EBITDA, reaffirmed higher full-year guidance, and a 14% 21-day stock uptrend with recent breakout strength. | Closed | +10.6% |